This premier online conference is set for
'The pursuit of breakthroughs in drug discovery demands effective communication across experience levels and technical disciplines,' expressed
The summit itself provides an essential forum for stakeholders, primarily across Spanish and Portuguese markets to engage with these innovations and consider their application in a field that is increasingly reliant on AI to streamline processes. These innovationsenhance research methodologies, and ultimately, deliver cost-effective solutions and profitability in the fast-evolving landscape of biotechnology. Within this dynamic context,
About The Ibero-American Chatbot and Conversational AI Summit
The Ibero-American Chatbot and Conversational AI Summit is a distinguished online event scheduled for
This conference is uniquely tailored to facilitate in-depth discussions on how conversational AI can be strategically utilized to streamline business operations, augment research capabilities, and enhance profitability. Through a blend of keynote speeches, case studies from leading brands, and interactive sessions, attendees will have the chance to glean valuable insights from experts across various regions.
With a commitment to inclusivity and knowledge-sharing, the summit offers complimentary registration, making it an accessible and valuable networking hub for professionals eager to delve into the cutting-edge of conversational AI technology.
About Oncotelic
Oncotelic (f/k/a
Further, Oncotelic acquired AL-101, during the 4th quarter of 2021, for the intranasal delivery of apomorphine. We intend to develop AL-101 for the treatment of Parkinson Disease, erectile dysfunction, female sexual disorder and hypoactive sexual desire disorder. All these ailments have a very large population suffering from them and there is a need for treatments for each.
Oncotelic's Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this communication regarding strategy, future operations, future financial position, prospects, plans and objectives of management are forward-looking statements. Words such as 'may', 'expect', 'anticipate' 'hope', 'vision', 'optimism', 'design', 'exciting', 'promising', 'will', 'conviction', 'estimate,' 'intend,' 'believe', 'quest for a cure of cancer', 'innovation-driven', 'paradigm-shift', 'high scientific merit', 'impact potential' and similar expressions are intended to identify forward-looking statements. Forward looking statements contained in this press release include, but are not limited to, statements about future plans related to the operations of the JV, taking the JV into an initial public offering or the success thereof, the progress, timing of clinical development, scope and success of future clinical trials, the reporting of clinical data for the Company's product candidates and the potential use of the Company's product candidates to treat various cancer indications as well as obtaining required regulatory approval to conduct clinical trials and upon granting of approval by the regulatory agencies, the successful marketing of the products; building and the success of our nanoparticle platform and the related success of launching the platform, the development of the Company's AI suite including but not limited to AI Chatbots, the public access to the Company's AI suite, the success of the development of the AI suite or any other AI technologies and whether if any or portion thereof the Company's AI suite or technologies will be commercialized and launched for sale. Each of these forward-looking statements involves risks and uncertainties, and actual results may differ materially from these forward-looking statements or may not occur at all. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during preclinical or clinical studies, clinical trial site activation or enrollment rates that are lower than expected, changes in expected or existing competition, changes in the regulatory environment, failure of collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes, taking the Company or its affiliates through initial public offerings. These risks are not exhaustive, the company faces known and unknown risks, including the risk factors described in the Company's Annual Report on Form 10-K/A filed with the
Contact:
Email: ir@oncotelic.com
(C) 2023 Electronic News Publishing, source